Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions

Abstract

SummaryBackground Skin mast cells are implicated as detrimental effector cells in various inflammatory skin diseases such as contact eczema, atopic dermatitis and psoriasis. Selective reduction of cutaneous mast cells, e.g. by inducing targeted apoptosis, might prove a rational and efficient therapeutic strategy in dermatoses negatively influenced by mast cells. Objectives The objective of the present study was to evaluate whether a lysosomotropic agent such as siramesine can cause apoptosis of mast cells present in psoriatic lesions. Materials and methods Punch biopsies were obtained from lesional and uninvolved skin in 25 patients with chronic plaque psoriasis. After incubation with siramesine, the number of tryptase-positive mast cells and their expression of interleukin (IL)-6 and IL-17 was analysed. Skin biopsies were digested to allow flow cytometric analysis of the drug's effect on cutaneous fibroblasts and keratinocytes. Results Siramesine caused a profound reduction in the total number of mast cells in both lesional and uninvolved psoriatic skin biopsies without affecting the gross morphology of the tissue. The drug reduced the density of IL-6-and IL-17-positive mast cells, and showed antiproliferative effects on epidermal keratinocytes but had no apparent cytotoxic effect on keratinocytes or dermal fibroblasts. Conclusions Considering the pathophysiology of psoriasis, the effects of siramesine on cutaneous mast cells may prove favourable from the therapeutic aspect. The results encourage further studies to assess the usefulness of siramesine and other lysosomotropic agents in the treatment of cutaneous mastocytoses and inflammatory skin diseases aggravated by dermal mast cells.

Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis

“…Anatomically, MCs are most prominently located perivascularly, in close proximity to nerve fibres, and around HFs. MCs may indeed play a more important role in psoriasis than is widely appreciated . Although it has been reported that the number of MCs is elevated in pruritic psoriatic lesions, one study has shown no difference in plasma histamine levels between psoriasis patients with or without pruritus; this might explain why <20% of itchy psoriasis patients respond to oral antihistamines .…”

Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms

“…Skin resident mast cells have a detrimental effect on different inflammatory skin diseases including psoriasis [63,64] and hence, selective reduction in the number or activity of mast cells has been proposed to overcome the symptoms of psoriasis. Mast cells release a myriad of primary and secondary inflammatory mediators [65].…”

Mast cells of the nail in psoriasis: the tip of the iceberg?

“…Psoriasis is a complex immune‐mediated disease affecting 2–4% of the population in Western countries. Apart from its negative influence on the skin and joints, the disease is associated with numerous comorbidities and has a detrimental effect on quality of life . Mast cells are known to participate in initiation and maintenance of chronic inflammatory responses such as psoriasis .…”

“…Continuous expression of E‐selectin in the synovium maintains the influx of circulating inflammatory cells into the joints, which may contribute to synovial hyperplasia, leading to an increased number of mast cells. Siramesine, a lysosomotropic drug, was recently studied by Hagforsen et al . on ex vivo psoriatic skin.…”

“…Epidermal mast cell detection may be a clear histopathological clue for underlying PsA and/or other systemic comorbidities that warrant investigation. Using lysosomotropic agents (topically or systemically) may be clinically useful in order to diminish mast‐cell‐mediated, proinflammatory influences in psoriasis and to reduce its subsequent comorbidities.…”